$GERN MASSIVE MOVE EXPECTED ON JUNE 15TH DATA RELEASE

If you fancy a flutter, GERN could be a great place to start, option traders are expecting a move of up to $40 % on Monday as a result of the outcome from the Phase Data results been released tomorrow at the HOC conference. Like any Bio stock it is risky to trade but can be very rewarding,so play carefully.

AVERAGE ANALYSTS PRICE TARGET $3.5
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 25%
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.